DongBang Medical동방메디컬
240550 · KOSDAQ · ₩240550 · 동방메디컬
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩13,558
vs the current price (₩5,060)
- Enterprise value
- ₩284B
- Equity value
- ₩284B
- WACC
- 7.2%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 168% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- To match today's price of ₩5,060, the model needs an operating margin of 7.0% every year (it uses 15.6%).
- Or revenue growth −27.4 points a year higher than assumed in each of the 5 years.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩8,692
- +71.8%
- Base
- ₩13,558
- +167.9%
- Bull
- ₩21,787
- +330.6%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (15.6%).
Revenue growth
- 8%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.
- 6.8%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.
- 5.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.
- 4.3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.
Business
- 15.6%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 3%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so a typical level.
- 4%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: not in the statements, so a typical level.
- 34.6%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.08%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-29.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 89 weeks of weekly returns against KOSPI (official index); raw beta 0.08, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.58%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩125B
- Net debt (borrowings and leases − cash and deposits)
- ₩4.8B
- + Stakes and investments
- ₩7.8B
- Associates, long-term financial assets and deposits (book value)
- − Minority interests
- ₩2.9B
- Shares
- 20,933,940
- Share price
- ₩5,060
- Market cap
- ₩106B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|
| Revenue | ₩105B | ₩114B | ₩135B | ₩144B | ₩152B | ₩159B | ₩164B |
| Growth | — | 8.0% | 8.0% | 6.8% | 5.5% | 4.3% | 3.0% |
| EBIT | ₩15B | ₩17B | ₩21B | ₩23B | ₩24B | ₩25B | ₩26B |
| EBIT margin | 14.3% | 15.0% | 15.6% | 15.6% | 15.6% | 15.6% | 15.6% |
| After-tax EBIT | ₩11B | ₩12B | ₩15B | ₩16B | ₩17B | ₩18B | ₩18B |
| + Depreciation | — | — | ₩4.1B | ₩4.3B | ₩4.6B | ₩4.8B | ₩4.9B |
| − Capital spending | — | — | ₩5.4B | ₩5.8B | ₩6.1B | ₩6.4B | ₩6.5B |
| − Working capital | — | ₩6.7B | ₩3.5B | ₩3.2B | ₩2.7B | ₩2.3B | ₩1.6B |
| Free cash flow | — | — | ₩10B | ₩12B | ₩13B | ₩14B | ₩15B |
| Discount factor | — | — | 0.933 | 0.870 | 0.811 | 0.756 | 0.705 |
| Present value | — | — | ₩9.8B | ₩10B | ₩11B | ₩11B | ₩11B |
Terminal value ₩329B, worth ₩232B today: 82% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.2% | ₩14,433 | ₩15,538 | ₩16,902 | ₩18,628 | ₩20,884 |
| 6.7% | ₩13,109 | ₩13,989 | ₩15,052 | ₩16,365 | ₩18,026 |
| 7.2% | ₩11,999 | ₩12,711 | ₩13,558 | ₩14,581 | ₩15,844 |
| 7.7% | ₩11,055 | ₩11,640 | ₩12,325 | ₩13,139 | ₩14,123 |
| 8.2% | ₩10,243 | ₩10,729 | ₩11,291 | ₩11,950 | ₩12,732 |
Now (TTM)
- Market cap
- ₩106B
- Enterprise value
- ₩111B
- P/E
- 6.6×
- P/B
- 0.8×
- P/S
- 0.8×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | |
|---|---|
| Price | ₩7,810 |
| Market cap | ₩163B |
| P/E | 14.0× |
| P/B | 1.3× |
| P/S | 1.4× |
| EV/EBITDA | — |
| Dividend yield | 0.0% |
Loading data for this company — check back soon
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| DongBang Medical | 6.6× | 0.8× | 0.8× | — | 0.0% |
| TSE | 27.5× | 6.1× | 5.1× | — | 0.2% |
| Kctech | 22.1× | 3.4× | 4.1× | 17.1× | 0.5% |
| Classys | 12.7× | 3.2× | 4.7× | 9.9× | 3.7% |
| Park Systems | 69.0× | 4.7× | 8.2× | — | 0.2% |
| DI | 42.2× | 5.8× | 2.6× | — | 0.6% |
| Curiox Biosystems | — | 21.3× | 182.0× | — | 0.0% |
| Similar companies (median) | 27.5× | 5.3× | 4.9× | 13.5× | 0.3% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: DongBang Medical / 동방메디컬 / 240550 / KRX:240550
Source: KRX statistical information